BioreclamationIVT is now BioIVT


BioIVT, formerly BioreclamationIVT, is a leading global provider of high-quality biological specimens and value-added services. We specialize in control and disease state samples including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. 

Our PHASEZERO Research Services team works collaboratively with clients to provide target and biomarker validation, phenotypic assays to characterize novel therapeutics, clinical assay development and in vitro hepatic modeling solutions. And as the world’s premier supplier of ADME-Tox model systems, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly discovered compounds and the effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in ELEVATING SCIENCE.

Learn about the new BioIVT!
BioIVT Corporate Video


BioIVT is a worldwide provider of human and animal biological specimens and value-added services to pharmaceutical, biotechnology, diagnostic, contract research organizations (CRO),  academic and government institutions.

Looking for a Product or Service?

Our new site has over 400 individual product pages featuring the complete capabilities of BioIVT.

Visit our Request A Quote page to learn how to find your product or service of interest.


The New FDA Draft Guidance on In Vitro DDI Studies: How Will It Impact You?

By Graham Dyck / March 15, 2018

In October 2017, the FDA published revised draft guidance on DDI studies, entitled In Vitro Metabolism and Transporter-Mediated Drug-Drug Interaction Studies.  The guidance is the 4th Drug-Drug Interaction (DDI) Guidance document released by the agency and replaces the previous Guidances published in 1997, 2006, and 2012. Dr. Ron Laethem, Lead In Vitro Services, at BioIVT… Read more »

Read More >